NasdaqGM - Nasdaq Real Time Price USD

Keros Therapeutics, Inc. (KROS)

Compare

17.12

+0.09

(+0.53%)

At close: December 23 at 4:00:01 PM EST

17.09

-0.03

(-0.18%)

After hours: 7:06:25 PM EST

Keros Therapeutics price target raised to $28 from $11 at Wells Fargo

Wells Fargo raised the firm’s price target on Keros Therapeutics (KROS) to $28 from $11 and keeps an Overweight rating on the shares. The safety findings announced in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept in combination with background therapy in patients with pulmonary arterial hypertension, “basically zeroed expectations,” though cash plus pipeline is worth more than where the stock is right now, the analyst tells investors in a research note. Published first on The

TipRanks 9 days ago

KROS
+0.53%
Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug

Keros Therapeutics stock plummeted Thursday after the company stopped giving higher doses in a lung disease study due to side effects.

Investor's Business Daily 11 days ago

KROS
+0.53%
Keros Therapeutics Prospects Still Strong Despite Cibotercept Hurdles, Wedbush Says

Keros Therapeutics' (KROS) efforts to develop new treatments for pulmonary arterial hypertension rem

PREMIUM
MT Newswires 11 days ago

KROS
+0.53%
Keros shares collapse on ‘unanticipated’ setback for lung disease drug

Safety concerns Keros observed in a Phase 2 trial triggered a stock selloff for what had been one of the sector’s most successful initial public offerings of the last four years, according to BioPharma Dive data.

BioPharma Dive 11 days ago

KROS
+0.53%
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has vo

GlobeNewswire 11 days ago

KROS
+0.53%
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1 weeksDurable clinical responses were associated with improvements in patient-reported measures of fatigue in MDS patients early, and with continued improvement over timeData from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can potentially ameliorate ineffect

GlobeNewswire 14 days ago

KROS
+0.53%
Takeda licensed for anaemia therapy by Keros Therapeutics

Takeda will make an upfront payment of $200m to Keros.

Pharmaceutical Technology 19 days ago

TAK

KROS
+0.53%
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

On Tuesday, Takeda Pharmaceutical Company Limited (NYSE:TAK) entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (NASDAQ:KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis. Also Read: Analyst Sees Keros Therapeutics

Benzinga 20 days ago

TAK

KROS
+0.53%
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered royalties on net sales LEXINGTON, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that a

GlobeNewswire 20 days ago

TAK

TKPHF

KROS
+0.53%
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the followin

GlobeNewswire 27 days ago

KROS
+0.53%
Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023)

Keros Therapeutics ( NASDAQ:KROS ) Third Quarter 2024 Results Key Financial Results Net loss: US$53.0m (loss widened by...

Simply Wall St. last month

KROS
+0.53%
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended September 30, 2024. “This con

GlobeNewswire last month

KROS
+0.53%
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentat

GlobeNewswire last month

KROS
+0.53%
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from its hematology program at the 66th American Society of Hematology (“ASH”

GlobeNewswire last month

KROS
+0.53%
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November

GlobeNewswire 2 months ago

KROS
+0.53%
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fires

GlobeNewswire 3 months ago

KROS
+0.53%
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Keros Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 66 to 86.

Investor's Business Daily 3 months ago

KROS
+0.53%
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the Company has closed screening for the TROPOS trial, a Phase 2 clinical trial of cibotercep

GlobeNewswire 3 months ago

KROS
+0.53%
Keros Therapeutics Reports Second Quarter 2024 Financial Results

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended June 30, 2024. “Keros continued to build upon the progress o

GlobeNewswire 4 months ago

KROS
+0.53%
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 5 months ago

KROS
+0.53%

Performance Overview

Return	KROS	S&P 500
YTD	-56.94%	+25.25%
1-Year	-55.19%	+25.65%
3-Year	-69.39%	+27.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Keros Therapeutics, Inc. (KROS)

Keros Therapeutics price target raised to $28 from $11 at Wells Fargo

Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug

Keros Therapeutics Prospects Still Strong Despite Cibotercept Hurdles, Wedbush Says

Keros shares collapse on ‘unanticipated’ setback for lung disease drug

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

Takeda licensed for anaemia therapy by Keros Therapeutics

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Keros Therapeutics Third Quarter 2024 Earnings: US$1.41 loss per share (vs US$1.33 loss in 3Q 2023)

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial

Keros Therapeutics Reports Second Quarter 2024 Financial Results

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Performance Overview